MedPharm expands topical and transdermal delivery services

A new location in Raleigh-Durham, North Carolina, close to the CDMO's Center of Excellence, will double its current footprint

MedPharm has announced it is expanding its CDMO services in topical and transdermal delivery by opening a new location in Raleigh-Durham, North Carolina.

The new facility, located within a few miles of the CDMO's current Center of Excellence, will support process development and clinical and small-scale commercial manufacturing for semi-solid and liquid pharmaceutical products.

Designed to meet all FDA, EMA and GMP requirements the new site boasts state-of-the-art design, operational support systems, technology and resource management, MedPharm said.

"MedPharm’s newest facility is an extension of our development services and will also support our client base with their clinical and commercial pipelines needs for topical and transdermal products globally," said Eugene Ciolfi, MedPharm’s President and CEO.

Less than two weeks ago, the company announced a £1.5-million investment into the refurbishment and expansion of its 15,000-sq. ft campus in Surrey, UK that will increase its UK laboratory space by 35%.

At the tail end of 2019, MedPharm completed a $4 million expansion of its North Carolina facility’s footprint to approximately 25,000 sq. ft. The expansion covered pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering.